Inflammatory bowel disease and pregnancy: an update

References

• Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol. Clin. North Am.28(2), 255–281, vii (1999).
   PubMed Web of Science ®Google Scholar
• Orholm M, Fonager K, Sorensen HT. Risk of ulcerative colitis and Crohn’s disease among offspring of patients with chronic inflammatory bowel disease. Am. J. Gastroenterol.94(11), 3236–3238 (1999).
   PubMedGoogle Scholar
• Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology100(6), 1638–1643 (1991).
   PubMed Web of Science ®Google Scholar
• Polito JM, Childs B, Mellits ED et al. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology111(3), 580–586 (1996).
   PubMed Web of Science ®Google Scholar
• Menken J, Trussell J, Larsen U. Age and infertility. Science233(4771), 1389–1394 (1986).
   PubMed Web of Science ®Google Scholar
• Olsen KO, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology122(1), 15–19 (2002).
   PubMedGoogle Scholar
• Hudson M, Flett G, Sinclair TS et al. Fertility and pregnancy in inflammatory bowel disease. Int. J. Gynaecol. Obstet.58(2), 229–237. (1997).
   PubMed Web of Science ®Google Scholar
• Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut55(11), 1575–1580 (2006).
   PubMed Web of Science ®Google Scholar
• Khosla R, Willoughby CP, Jewell DP. Crohn’s disease and pregnancy. Gut25(1), 52–56 (1984).
   PubMed Web of Science ®Google Scholar
• Johnson P, Richard C, Ravid A et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon Rectum47(7), 1119–1126 (2004).
   PubMed Web of Science ®Google Scholar
• Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm. Bowel Dis.13(5), 591–599 (2007).
   PubMed Web of Science ®Google Scholar
• Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm. Bowel Dis.14(12), 1736–1750 (2008).
   PubMed Web of Science ®Google Scholar
• Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm. Bowel Dis.15(5), 720–725 (2009).
   PubMed Web of Science ®Google Scholar
• Gorgun E, Remzi FH, Goldberg JM et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery136(4), 795–803 (2004).
   PubMed Web of Science ®Google Scholar
• Lepisto A, Sarna S, Tiitinen A, Jarvinen HJ. Female fertility and childbirth after ileal pouch-anal anastomosis for ulcerative colitis. Br. J. Surg.94(4), 478–482 (2007).
   PubMed Web of Science ®Google Scholar
• Cornish JA, Tan E, Teare J et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis. Colon Rectum50(8), 1128–1138 (2007).
   PubMed Web of Science ®Google Scholar
• Arkuran C, McComb P. Crohn’s disease and tubal infertility: the effect of adhesion formation. Clin. Exp. Obstet. Gynecol.27(1), 12–13 (2000).
   PubMedGoogle Scholar
• Oresland T, Palmblad S, Ellstrom M et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int. J. Colorectal Dis.9(2), 77–81 (1994).
   PubMed Web of Science ®Google Scholar
• Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int. J. Colorectal Dis.12(4), 220–224 (1997).
   PubMed Web of Science ®Google Scholar
• Stein SL, Michelassi F. How can fecundity be preserved in patients undergoing pelvic surgery? Nat. Clin. Pract. Gastroenterol. Hepatol.5(6), 308–309 (2008).
   PubMedGoogle Scholar
• Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA273(24), 1933–1936 (1995).
   PubMed Web of Science ®Google Scholar
• Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal–fetal interface. J. Immunol.151(9), 4562–4573 (1993).
   PubMed Web of Science ®Google Scholar
• Winger EE, Reed JL, Ashoush S et al. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am. J. Reprod. Immunol.61(2), 113–120 (2009).
   PubMed Web of Science ®Google Scholar
• Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn’s disease: a follow-up study based on linkage between national registries. Am. J. Gastroenterol.93(12), 2426–2430 (1998).
   PubMed Web of Science ®Google Scholar
• Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease – a population-based cohort study. Am. J. Obstet. Gynecol.177(4), 942–946 (1997).
   PubMed Web of Science ®Google Scholar
• Norgard B, Fonager K, Sorensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am. J. Gastroenterol.95(11), 3165–3170 (2000).
   PubMed Web of Science ®Google Scholar
• Lin HC, Chiu CC, Chen SF et al. Ulcerative colitis and pregnancy outcomes in an Asian population. Am. J. Gastroenterol.105(2), 387–394 (2010).
   PubMedGoogle Scholar
• Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am. J. Gastroenterol.97(3), 641–648 (2002).
   PubMed Web of Science ®Google Scholar
• Norgard B, Puho E, Pedersen L, Czeizel AE, Sorensen HT. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am. J. Gastroenterol.98(9), 2006–2010 (2003).
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Sandborn WJ, Li DK et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology133(4), 1106–1112 (2007).
   PubMed Web of Science ®Google Scholar
• Dotan I, Alper A, Rachmilewitz D et al. The effect of inflammatory bowel disease during pregnancy on long-term helath and illness in children of IBD patients – a multicenter Israeli study. Gastroenterology136(5, Suppl. 1), A-15 (2009).
   Google Scholar
• Morales M, Berney T, Jenny A, Morel P, Extermann P. Crohn’s disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology47(36), 1595–1598 (2000).
   PubMedGoogle Scholar
• Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand. J. Gastroenterol.18(6), 735–742 (1983).
   PubMed Web of Science ®Google Scholar
• Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J. Matern. Fetal Neonatal Med.15(4), 237–241 (2004).
   PubMedGoogle Scholar
• Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am. J. Obstet. Gynecol.160(4), 998–1001 (1989).
   PubMed Web of Science ®Google Scholar
• Moser MA, Okun NB, Mayes DC, Bailey RJ. Crohn’s disease, pregnancy, and birth weight. Am. J. Gastroenterol.95(4), 1021–1026 (2000).
   PubMedGoogle Scholar
• Nielsen OH, Andreasson B, Bondesen S, Jacobsen O, Jarnum S. Pregnancy in Crohn’s disease. Scand. J. Gastroenterol.19(6), 724–732. (1984).
   PubMed Web of Science ®Google Scholar
• Agret F, Cosnes J, Hassani Z et al. Impact of pregnancy on the clinical activity of Crohn’s disease. Aliment Pharmacol. Ther.21(5), 509–513 (2005).
   PubMed Web of Science ®Google Scholar
• Ubina-Aznar E, De Sola-Earle C, Rivera-Irigoin R et al. Crohn’s disease and pregnancy. A descriptive and retrospective study. Gastroenterol. Hepatol.29(5), 277–280 (2006).
   PubMedGoogle Scholar
• Castiglione F, Pignata S, Morace F et al. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital. J. Gastroenterol.28(4), 199–204 (1996).
   PubMedGoogle Scholar
• Riis L, Vind I, Politi P et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am. J. Gastroenterol.101(7), 1539–1545 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson JL, Hughes KA, Smith AG et al. Maternal–fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N. Engl. J. Med.329(7), 466–471 (1993).
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV, Zappoli P et al. Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Liver Transpl.13(4), 552–557 (2007).
   PubMedGoogle Scholar
• Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am. J. Gastroenterol.99(8), 1523–1526 (2004).
   PubMed Web of Science ®Google Scholar
• Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am. J. Gastroenterol.100(1), 102–105 (2005).
   PubMed Web of Science ®Google Scholar
• Salem ML. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr. Drug Targets Inflamm. Allergy3(1), 97–104 (2004).
   PubMedGoogle Scholar
• Ostensen M, Forger F, Nelson JL et al. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann. Rheum. Dis.64(6), 839–844 (2005).
   PubMed Web of Science ®Google Scholar
• Draca S, Levic Z. The possible role of prolactin in the immunopathogenesis of multiple sclerosis. Med. Hypotheses47(2), 89–92 (1996).
   PubMed Web of Science ®Google Scholar
• Barrett JH, Brennan P, Fiddler M, Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum.43(5), 1010–1015 (2000).
   PubMed Web of Science ®Google Scholar
• Berczi I. The role of the growth and lactogenic hormone family in immune function. Neuroimmunomodulation1(4), 201–216 (1994).
   PubMedGoogle Scholar
• Moffatt DC, Ilnyckyj A, Bernstein CN. A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am. J. Gastroenterol.104(10), 2517–2523 (2009).
   PubMed Web of Science ®Google Scholar
• Klement E, Reif S. Breastfeeding and risk of inflammatory bowel disease. Am. J. Clin. Nutr.82(2), 486 (2005).
   PubMedGoogle Scholar
• Jantchou P, Turck D, Balde M, Gower-Rousseau C. Breastfeeding and risk of inflammatory bowel disease: results of a pediatric, population-based, case–control study. Am. J. Clin. Nutr.82(2), 485–486 (2005).
   PubMed Web of Science ®Google Scholar
• Kilpatrick CC, Monga M. Approach to the acute abdomen in pregnancy. Obstet. Gynecol. Clin. North Am.34(3), 389–402 (2007).
   PubMed Web of Science ®Google Scholar
• Dozois EJ, Wolff BG, Tremaine WJ et al. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis. Colon Rectum49(1), 64–73 (2005).
   Google Scholar
• Haq AI, Sahai A, Hallwoth S, Rampton DS, Dorudi S. Synchronous colectomy and caesarean section for fulminant ulcerative colitis: case report and review of the literature. Int. J. Colorectal Dis.21(5), 465–469 (2005).
   PubMedGoogle Scholar
• Mahadevan U, Martin C, Sandler R et al. A multi-center national prospective study of pregnancy and neonatal outcomes in women with inflammatory bowel disease exposed to immunomodulators and biologic therapy. Gastroenterology136(5, Suppl. 1), A-88 (2009).
   Google Scholar
• Cornish J, Tan E, Teare J et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut56(6), 830–837 (2007).
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn’s disease. Am. J. Gastroenterol.90(11), 1918–1922 (1995).
   PubMed Web of Science ®Google Scholar
• Beniada A, Benoist G, Maurel J, Dreyfus M. Inflammatory bowel disease and pregnancy: report of 76 cases and review of the literature. J. Gynecol. Obstet. Biol. Reprod. (Paris)34(6), 581–588 (2005).
   PubMedGoogle Scholar
• Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn’s disease and pregnancy: role of the mode of delivery. Am. J. Gastroenterol.94(11), 3274–3278 (1999).
   PubMed Web of Science ®Google Scholar
• Hahnloser D, Pemberton JH, Wolff BG et al. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. Dis. Colon Rectum47(7), 1127–1135 (2004).
   PubMedGoogle Scholar
• Zelinkova Z, Mensink PB, Dees J, Kuipers EJ, van der Woude CJ. Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand. J. Gastroenterol.45(1), 46–50 (2010).
   PubMed Web of Science ®Google Scholar
• Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology105(4), 1057–1060 (1993).
   PubMed Web of Science ®Google Scholar
• Marteau P, Tennenbaum R, Elefant E, Lemann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment. Pharmacol. Ther.12(11), 1101–1108 (1998).
   PubMed Web of Science ®Google Scholar
• Trallori G, d’Albasio G, Bardazzi G et al. 5-aminosalicylic acid in pregnancy: clinical report. Ital. J. Gastroenterol.26(2), 75–78 (1994).
   PubMedGoogle Scholar
• Norgard B, Fonager K, Pedersen L, Jacobsen BA, Sorensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut52(2), 243–247 (2003).
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Park YH, Veerasuntharam G et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology114(1), 23–28 (1998).
   PubMed Web of Science ®Google Scholar
• Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet1(8634), 383 (1989).
   PubMed Web of Science ®Google Scholar
• Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta. Paediatr. Scand.76(1), 137–142 (1987).
   PubMed Web of Science ®Google Scholar
• Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol.172(2 Pt 1), 525–529 (1995).
   PubMed Web of Science ®Google Scholar
• Caro-Paton T, Carvajal A, Martin de Diego I et al. Is metronidazole teratogenic? A meta-analysis. Br. J. Clin. Pharmacol.44(2), 179–182 (1997).
   PubMed Web of Science ®Google Scholar
• Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet. Gynecol.82(3), 348–352 (1993).
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Larsen H, Jensen ES et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J. Antimicrob. Chemother.44(6), 854–856 (1999).
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology63(5), 186–192 (2001).
   PubMedGoogle Scholar
• Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br. J. Obstet. Gynaecol.105(3), 322–327 (1998).
   PubMedGoogle Scholar
• American Academy of Pediatrics. Committee on Drugs. Naloxone use in newborns. Pediatrics65(3), 667–669 (1980).
   PubMedGoogle Scholar
• Niebyl JR. Antibiotics and other anti-infective agents in pregnancy and lactation. Am. J. Perinatol.20(8), 405–414 (2003).
   PubMed Web of Science ®Google Scholar
• Larsen H, Nielsen GL, Schonheyder HC, Olesen C, Sorensen HT. Birth outcome following maternal use of fluoroquinolones. Int. J. Antimicrob. Agents18(3), 259–262 (2001).
   PubMed Web of Science ®Google Scholar
• Loebstein R, Addis A, Ho E et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob. Agents Chemother.42(6), 1336–1339 (1998).
   PubMed Web of Science ®Google Scholar
• Briggs G. Drugs in Pregnancy and Lactation.Briggs G, Yaffe Sumner FR (Eds). Lippincott Williams & Wilkins, PA, USA (2005).
   Google Scholar
• Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur. J. Obstet. Gynecol. Reprod. Biol.97(2), 188–192 (2001).
   PubMed Web of Science ®Google Scholar
• Berkovitch M, Diav-Citrin O, Greenberg R et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br. J. Clin. Pharmacol.58(3), 298–302 (2004).
   PubMed Web of Science ®Google Scholar
• Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am. J. Med. Genet.86(3), 242–244 (1999).
   PubMed Web of Science ®Google Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology62(6), 385–392 (2000).
   PubMedGoogle Scholar
• Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod. Toxicol.18(1), 93–101 (2004).
   PubMed Web of Science ®Google Scholar
• Armenti VT, Moritz MJ, Cardonick EH, Davison JM. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs62(16), 2361–2375 (2002).
   PubMed Web of Science ®Google Scholar
• Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn’s disease and adrenal suppression in her newborn. Neonatology94(4), 306–309 (2008).
   PubMed Web of Science ®Google Scholar
• Beaulieu DB, Ananthakrishnan AN, Issa M et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm. Bowel Dis.15(1), 25–28 (2009).
   PubMed Web of Science ®Google Scholar
• Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr. Med. Res. Opin.21(7), 1075–1084 (2005).
   PubMed Web of Science ®Google Scholar
• Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J. Allergy Clin. Immunol.111(4), 736–742 (2003).
   PubMed Web of Science ®Google Scholar
• Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology60(1), 10–12 (1999).
   PubMedGoogle Scholar
• American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics108, 776–789 (2001).
   PubMed Web of Science ®Google Scholar
• Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology65(5), 240–261 (2002).
   PubMedGoogle Scholar
• de Boer NK, Jarbandhan SV, de Graaf P et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am. J. Gastroenterol.101(6), 1390–1392 (2006).
   PubMed Web of Science ®Google Scholar
• Norgard B, Pedersen L, Fonager K, Rasmussen SN, Sorensen HT. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol. Ther.17(6), 827–834 (2003).
   PubMed Web of Science ®Google Scholar
• Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology99(2), 443–446 (1990).
   PubMed Web of Science ®Google Scholar
• Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology124(1), 9–17 (2003).
   PubMed Web of Science ®Google Scholar
• Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion62(4), 249–254 (2000).
   PubMed Web of Science ®Google Scholar
• Moskovitz DN, Bodian C, Chapman ML et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am. J. Gastroenterol.99(4), 656–661 (2004).
   PubMed Web of Science ®Google Scholar
• Zlatanic J, Korelitz BI, Rajapakse R et al. Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease. J. Clin. Gastroenterol.36(4), 303–309 (2003).
   PubMedGoogle Scholar
• Coelho J, Beaugerie L, Colombel J-F et al. Pregnancy outcome in inflammatory bowel disease for women treated with thiopurine: cohort from the CESAME study. Gastroenterology136(5 Suppl. 1), A-27 (2009).
   Google Scholar
• Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am. J. Gastroenterol.102(7), 1406–1413 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein LH, Dolinsky G, Greenberg R et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res. A Clin. Mol. Teratol.79(10), 696–701 (2007).
   PubMed Web of Science ®Google Scholar
• Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res. A Clin. Mol. Teratol.85(7), 647–654 (2009).
   PubMed Web of Science ®Google Scholar
• Moretti ME, Verjee Z, Ito S, Koren G. Breast-feeding during maternal use of azathioprine. Ann. Pharmacother.40(12), 2269–2272 (2006).
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gearry RB, Roberts RL et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br. J. Clin. Pharmacol.62(4), 453–456 (2006).
   PubMed Web of Science ®Google Scholar
• Sau A, Clarke S, Bass J et al. Azathioprine and breastfeeding: is it safe? BJOG114(4), 498–501 (2007).
   PubMed Web of Science ®Google Scholar
• Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol. Ther.28(10), 1209–1213 (2008).
   PubMed Web of Science ®Google Scholar
• Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation71(8), 1051–1055 (2001).
   PubMed Web of Science ®Google Scholar
• Nagy S, Bush MC, Berkowitz R, Fishbein TM, Gomez-Lobo V. Pregnancy outcome in liver transplant recipients. Obstet. Gynecol.102(1), 121–128 (2003).
   PubMed Web of Science ®Google Scholar
• Angelberger S, Reinisch W, Dejaco C. Prevention of abortion by ciclosporin treatment of fulminant ulcerative colitis during pregnancy. Gut55(9), 1364–1365 (2006).
   PubMedGoogle Scholar
• Bertschinger P, Himmelmann A, Risti B, Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am. J. Gastroenterol.90(2), 330 (1995).
   PubMed Web of Science ®Google Scholar
• Reindl W, Schmid RM, Huber W. Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases. Gut56(7), 1019 (2007).
   PubMed Web of Science ®Google Scholar
• Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am. J. Gastroenterol.103(5), 1203–1209 (2008).
   PubMed Web of Science ®Google Scholar
• Branche J, Cortot A, Bourreille A et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm. Bowel Dis.15(7), 1044–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Jain A, Venkataramanan R, Fung JJ et al. Pregnancy after liver transplantation under tacrolimus. Transplantation64(4), 559–565 (1997).
   PubMed Web of Science ®Google Scholar
• Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl. Int.13(Suppl. 1), S299–S300 (2000).
   PubMedGoogle Scholar
• Jain AB, Reyes J, Marcos A et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years. Transplantation76(5), 827–832 (2003).
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut54(12), 1822–1823 (2005).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Simister NE. Placental transport of immunoglobulin G. Vaccine21(24), 3365–3369 (2003).
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol.4(10), 1255–1258 (2006).
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Terdiman J, Church J et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology132(4 Suppl. 2), A144 (2007).
   Google Scholar
• Lichtenstein G, Cohen RD, Feagan BG et al. Safety of infliximab in Crohn’s disease: data from the 5000-patient TREAT registry. Gastroenterology126(4 Suppl.), A54 (2004).
   Google Scholar
• Katz JA, Antoni C, Keenan GF et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am. J. Gastroenterol.99(12), 2385–2392 (2004).
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Kane S, Sandborn WJ et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment Pharmacol. Ther.21(6), 733–738 (2005).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Intentional treatmetn with infliximab during pregnancy in women with inflammatory bowel disease. Gastroenterology132(4 Suppl. 2), Abstract 958 (2007).
   Google Scholar
• Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J. Clin. Gastroenterol.43(7), 613–616 (2009).
   PubMed Web of Science ®Google Scholar
• Peltier M, James D, Ford J et al. Infliximab levels in breast-milk of a nursing Crohn’s patient. Am. J. Gastroenterol.96(9 Suppl. 1), P258 (2001).
   PubMedGoogle Scholar
• Anolik JH, Ravikumar R, Barnard J et al.Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol.180(2), 688–692 (2008).
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Kane S, Church J, Vasiliauskas E, Sandborn W, Dubinsky M. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology134(4 Suppl. 1), A69 (2008).
   Web of Science ®Google Scholar
• Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol.34(2), 272–279 (2007).
   PubMed Web of Science ®Google Scholar
• Melmed GY, Agarwal N, Frenck RW et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am. J. Gastroenterol.105(1), 148–154 (2010).
   PubMed Web of Science ®Google Scholar
• Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn’s disease of an ileoanal pouch during pregnancy. Dig. Dis. Sci.51(11), 2045–2047 (2006).
   PubMed Web of Science ®Google Scholar
• Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm. Bowel Dis.12(8), 827 -828 (2006).
   PubMed Web of Science ®Google Scholar
• Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut54(6), 890 (2005).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen OO, Schreiber S et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin. Gastroenterol. Hepatol. DOI:10.1016/j.cgh.2010.01.014 (2010) (Epub ahead of print).
   Google Scholar
• Nesbitt A, Brown D, Stephens S, Foulkes R. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus pegylated Fab’. Am. J. Gastroenterol.101(S2), Abstract 119 (2006).
   Google Scholar
• Mahadevan U, Siegel C, Abreu M. Certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology136(5), 960 (2009).
   Google Scholar
• Rossi E, Costa M. Fish oil derivatives as a prophylaxis of recurrent miscarriage associated with antiphospholipid antibodies (APL): a pilot study. Lupus2(5), 319–323 (1993).
   PubMed Web of Science ®Google Scholar
• Olsen SF, Sorensen JD, Secher NJ et al. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet339(8800), 1003–1007 (1992).
   PubMed Web of Science ®Google Scholar
• Patlas N, Golomb G, Yaffe P et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology60(2), 68–73 (1999).
   PubMedGoogle Scholar
• Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod. Toxicol.22(4), 578–579 (2006).
   PubMed Web of Science ®Google Scholar
• Levy S, Fayez I, Taguchi N et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone44(3), 428–430 (2009).
   PubMed Web of Science ®Google Scholar
• Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet. Gynecol.114(6), 1326–1331 (2009).
   PubMed Web of Science ®Google Scholar
• Qureshi WA, Rajan E, Adler DG et al. ASGE guideline: guidelines for endoscopy in pregnant and lactating women. Gastrointest. Endosc.61(3), 357–362 (2005).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology134(7), 1861–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Administration FDA. Regulations. 44, 37434–37467 (1980).
   Google Scholar
• Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology131(1), 278–282 (2006).
   PubMed Web of Science ®Google Scholar